These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 21303472)

  • 1. Rituximab and lupus interstitial lung disease: friend or foe?
    Efthimiou P; Kukar M; Hersh A
    Int J Rheum Dis; 2011 Feb; 14(1):e3-4. PubMed ID: 21303472
    [No Abstract]   [Full Text] [Related]  

  • 2. First report of improvement of coeliac disease in a patient with Sjögren's syndrome treated with rituximab.
    Nikiphorou E; Hall FC
    Rheumatology (Oxford); 2014 Oct; 53(10):1906-7. PubMed ID: 24729401
    [No Abstract]   [Full Text] [Related]  

  • 3. Shrinking lung syndrome successfully treated with rituximab and cyclophosphamide.
    Langenskiöld E; Bonetti A; Fitting JW; Heinzer R; Dudler J; Spertini F; Lazor R
    Respiration; 2012; 84(2):144-9. PubMed ID: 22301521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocilizumab for refractory organising pneumonia associated with Sjögren's disease.
    Justet A; Ottaviani S; Dieudé P; Taillé C
    BMJ Case Rep; 2015 May; 2015():. PubMed ID: 25976199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dramatic reversal of lymphocytic interstitial pneumonitis in Sjögren's syndrome with rituximab.
    Swartz MA; Vivino FB
    J Clin Rheumatol; 2011 Dec; 17(8):454. PubMed ID: 22126805
    [No Abstract]   [Full Text] [Related]  

  • 6. Pulmonary manifestations of Sjögren's syndrome.
    Shi JH; Liu HR; Xu WB; Feng RE; Zhang ZH; Tian XL; Zhu YJ
    Respiration; 2009; 78(4):377-86. PubMed ID: 19390161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Considerations of Lung Involvement in Rheumatologic Disease.
    Robles-Perez A; Molina-Molina M
    Respiration; 2015; 90(4):265-74. PubMed ID: 26461464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab therapy in primary Sjögren's syndrome with interstitial lung disease: a retrospective cohort study.
    Chen MH; Chen CK; Chou HP; Chen MH; Tsai CY; Chang DM
    Clin Exp Rheumatol; 2016; 34(6):1077-1084. PubMed ID: 27607895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment approaches in primary Sjogren syndrome.
    Vissink A; Kallenberg CG; Bootsma H
    JAMA; 2010 Nov; 304(18):2015-6; author reply 2016. PubMed ID: 21063008
    [No Abstract]   [Full Text] [Related]  

  • 10. Complete remission of protein-losing gastroenteropathy associated with Sjögren's syndrome by B cell-targeted therapy with rituximab.
    Uraoka Y; Tanigawa T; Watanabe K; Machida H; Okazaki H; Yamagami H; Watanabe K; Tominaga K; Watanabe T; Fujiwara Y; Arakawa T
    Am J Gastroenterol; 2012 Aug; 107(8):1266-8. PubMed ID: 22859008
    [No Abstract]   [Full Text] [Related]  

  • 11. Targetoid-like Lesions in the Setting of Systemic Lupus Erythematosus: A Case of Rowell Syndrome.
    Ward JM; Hess JN; Davis LS
    J Rheumatol; 2020 Feb; 47(2):298-299. PubMed ID: 32007943
    [No Abstract]   [Full Text] [Related]  

  • 12. [Efficiency of rituximab in an unusual form of primary Sjögren's syndrome: a case report].
    Mrabet D; Meddeb N; Sahli H; Saadi F; Chéour E; Elleuch M; Sellami S
    Therapie; 2010; 65(6):581-3. PubMed ID: 23189757
    [No Abstract]   [Full Text] [Related]  

  • 13. Hydroxycholoroquine-induced hyperpigmentation.
    Mir A; Boyd KP; Meehan SA; McLellan B
    Dermatol Online J; 2013 Dec; 19(12):20723. PubMed ID: 24365014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome.
    Marie I; Dominique S; Janvresse A; Levesque H; Menard JF
    Respir Med; 2012 Apr; 106(4):581-7. PubMed ID: 22280877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance of rituximab treatment in a patient with primary Sjögren's syndrome.
    Lehner GF; Brunner-Palka M; Rettenbacher T; Schmidauer R; Herold M
    Rheumatology (Oxford); 2014 Jul; 53(7):1349-50. PubMed ID: 24446469
    [No Abstract]   [Full Text] [Related]  

  • 16. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.
    Ramos-Casals M; García-Hernández FJ; de Ramón E; Callejas JL; Martínez-Berriotxoa A; Pallarés L; Caminal-Montero L; Selva-O'Callaghan A; Oristrell J; Hidalgo C; Pérez-Alvarez R; Micó ML; Medrano F; Gómez de la Torre R; Díaz-Lagares C; Camps M; Ortego N; Sánchez-Román J;
    Clin Exp Rheumatol; 2010; 28(4):468-76. PubMed ID: 20525449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoimmune haemolytic anaemia as an initial presentation of primary Sjögren syndrome.
    Subbarayudu B; Sharma MS; Sreemannarayana P
    Intern Med J; 2014 Dec; 44(12a):1259-61. PubMed ID: 25442764
    [No Abstract]   [Full Text] [Related]  

  • 18. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.
    Gottenberg JE; Guillevin L; Lambotte O; Combe B; Allanore Y; Cantagrel A; Larroche C; Soubrier M; Bouillet L; Dougados M; Fain O; Farge D; Kyndt X; Lortholary O; Masson C; Moura B; Remy P; Thomas T; Wendling D; Anaya JM; Sibilia J; Mariette X;
    Ann Rheum Dis; 2005 Jun; 64(6):913-20. PubMed ID: 15550531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial.
    Moerman RV; Arends S; Meiners PM; Brouwer E; Spijkervet FK; Kroese FG; Vissink A; Bootsma H
    Ann Rheum Dis; 2014 Feb; 73(2):472-4. PubMed ID: 23940214
    [No Abstract]   [Full Text] [Related]  

  • 20. [Rituximab therapy for severe pediatric systemic lupus erythematosus].
    Su GX; Wu FQ; Wang F; Zhou ZX; Huang XL; Lu J
    Zhonghua Er Ke Za Zhi; 2012 Sep; 50(9):697-704. PubMed ID: 23158822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.